632eP Prevalence of ESR1 mutations in ER+/HER2- advanced breast cancer (aBC) patients treated with everolimus after CDK4/6 inhibitors
François C. Bocquet(Centre National de la Recherche Scientifique), Alice Rudolph, Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Finlay MacDougall(IQVIA (United Kingdom)), Michelle Quinlan(Nottingham University Hospitals NHS Trust), Luísa Lopes-Conceição(IPO Porto), C. Callens(Institut Curie), Sabrina Uhrig(Friedrich-Alexander-Universität Erlangen-Nürnberg), C. Lee(IQVIA (United Kingdom)), Ana Sofia Patrão(IPO Porto), C. Turcan(IQVIA (United Kingdom)), Benedikt Maissenhaelter(IQVIA (United Kingdom)), M. Campone(Institut de Cancérologie de l'Ouest), Philip Quinlan(Nottingham Biomedical Research Centre), P Cottu(Institut Curie), Hanna Huebner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), Peter A. Fasching(Universitätsklinikum Erlangen)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
|PLoS ONE|2015|906
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716